drugset / Trial / NCT04475224
Phase 3 Study of KP-100IT in Subjects With Acute Spinal Cord Injury
NaSingle-groupOpen-labelTreatment
Summary
This study is non-randomized, multicenter, confirmatory study by intrathecal administration of KP-100IT, code of HGF (Hepatocyte Growth Factor ) formulation for intrathecal injection, in subjects with acute spinal cord injury.
Timeline
- Start
- 2020-07-13
- Primary completion
- 2022-12-31
- Completion
- 2023-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HEPATOPOIETIN-A | Protein / enzyme biologic | 0.6 mg | Intrathecal |